<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4CB92F40-4E51-4027-B354-8C9737DBBCAD"><gtr:id>4CB92F40-4E51-4027-B354-8C9737DBBCAD</gtr:id><gtr:name>University of Tromsoe</gtr:name><gtr:address><gtr:line1>Arctic University of Norway</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9"><gtr:id>ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9</gtr:id><gtr:name>Curie Institute Paris (Institut Curie)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC68D4D9-FDF1-4BA8-826F-1AF5D36C82CE"><gtr:id>FC68D4D9-FDF1-4BA8-826F-1AF5D36C82CE</gtr:id><gtr:name>Centre for Genomic Regulation (CRG)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/335DFBB5-7BB6-448B-AFD4-1904C4D9A808"><gtr:id>335DFBB5-7BB6-448B-AFD4-1904C4D9A808</gtr:id><gtr:name>Vlaams Instituut Biotechnologie (VIB)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F94E0EA2-DA20-4E08-9841-2A69C2FEA91D"><gtr:id>F94E0EA2-DA20-4E08-9841-2A69C2FEA91D</gtr:id><gtr:name>Institute for Molecular Medicine Finland</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0F15002C-C70C-4AD9-B432-E950F6B2FDFD"><gtr:id>0F15002C-C70C-4AD9-B432-E950F6B2FDFD</gtr:id><gtr:name>European Institute of Oncology</gtr:name><gtr:address><gtr:line1>Via Ripamonti 435</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F4DC8F58-AC06-4EB1-976C-EAA0136CC12F"><gtr:id>F4DC8F58-AC06-4EB1-976C-EAA0136CC12F</gtr:id><gtr:name>Museu da Lourinh?</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/103D3F37-4066-444D-93DA-A10CF99F10F5"><gtr:id>103D3F37-4066-444D-93DA-A10CF99F10F5</gtr:id><gtr:name>Austrian Academy of Sciences</gtr:name><gtr:address><gtr:line1>Lazarettgasse 14</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39C210D7-B8AA-4A08-A580-FEAB7BACD30E"><gtr:id>39C210D7-B8AA-4A08-A580-FEAB7BACD30E</gtr:id><gtr:name>Friedrich Miescher Inst of Biomed Res</gtr:name><gtr:address><gtr:line1>Maulbeerstrasse 66</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C06AF2EB-8689-4D6A-B151-4DD4BEA85138"><gtr:id>C06AF2EB-8689-4D6A-B151-4DD4BEA85138</gtr:id><gtr:name>Central European Institute of Technology</gtr:name><gtr:address><gtr:line1>Central European Institute of Technology</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A22541F-DA58-481E-8D0C-C4BCF4EA030E"><gtr:id>9A22541F-DA58-481E-8D0C-C4BCF4EA030E</gtr:id><gtr:name>EMBL - European Bioinformatics Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB10 1SD</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E1649C06-DC81-4A08-8A23-F5B65BB6C670"><gtr:id>E1649C06-DC81-4A08-8A23-F5B65BB6C670</gtr:id><gtr:name>Babraham Institute</gtr:name><gtr:address><gtr:line1>Babraham Research Campus</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB22 3AT</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4CB92F40-4E51-4027-B354-8C9737DBBCAD"><gtr:id>4CB92F40-4E51-4027-B354-8C9737DBBCAD</gtr:id><gtr:name>University of Tromsoe</gtr:name><gtr:address><gtr:line1>Arctic University of Norway</gtr:line1><gtr:region>Outside UK</gtr:region><gtr:country>Norway</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9"><gtr:id>ADC59AFE-2986-4C0D-94F5-7E04B66E9AF9</gtr:id><gtr:name>Curie Institute Paris (Institut Curie)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA"><gtr:id>1D3C9ADE-5860-4017-88E9-BCDCD95A7CBA</gtr:id><gtr:name>University of Bath</gtr:name><gtr:address><gtr:line1>Claverton Down</gtr:line1><gtr:city>Bath</gtr:city><gtr:postCode>BA2 7AY</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC68D4D9-FDF1-4BA8-826F-1AF5D36C82CE"><gtr:id>FC68D4D9-FDF1-4BA8-826F-1AF5D36C82CE</gtr:id><gtr:name>Centre for Genomic Regulation (CRG)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/335DFBB5-7BB6-448B-AFD4-1904C4D9A808"><gtr:id>335DFBB5-7BB6-448B-AFD4-1904C4D9A808</gtr:id><gtr:name>Vlaams Instituut Biotechnologie (VIB)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F94E0EA2-DA20-4E08-9841-2A69C2FEA91D"><gtr:id>F94E0EA2-DA20-4E08-9841-2A69C2FEA91D</gtr:id><gtr:name>Institute for Molecular Medicine Finland</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0F15002C-C70C-4AD9-B432-E950F6B2FDFD"><gtr:id>0F15002C-C70C-4AD9-B432-E950F6B2FDFD</gtr:id><gtr:name>European Institute of Oncology</gtr:name><gtr:address><gtr:line1>Via Ripamonti 435</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAE32A25-51D3-49EF-998F-281B3A47C212"><gtr:id>FAE32A25-51D3-49EF-998F-281B3A47C212</gtr:id><gtr:name>Helmholtz Association of German Research Centres</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F4DC8F58-AC06-4EB1-976C-EAA0136CC12F"><gtr:id>F4DC8F58-AC06-4EB1-976C-EAA0136CC12F</gtr:id><gtr:name>Museu da Lourinh?</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/103D3F37-4066-444D-93DA-A10CF99F10F5"><gtr:id>103D3F37-4066-444D-93DA-A10CF99F10F5</gtr:id><gtr:name>Austrian Academy of Sciences</gtr:name><gtr:address><gtr:line1>Lazarettgasse 14</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78"><gtr:id>C1CE3B13-A79B-48B7-9B8D-97BC9C07DC78</gtr:id><gtr:name>Netherlands Cancer Institute</gtr:name><gtr:address><gtr:line1>Plesmanlaan 121</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39C210D7-B8AA-4A08-A580-FEAB7BACD30E"><gtr:id>39C210D7-B8AA-4A08-A580-FEAB7BACD30E</gtr:id><gtr:name>Friedrich Miescher Inst of Biomed Res</gtr:name><gtr:address><gtr:line1>Maulbeerstrasse 66</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C06AF2EB-8689-4D6A-B151-4DD4BEA85138"><gtr:id>C06AF2EB-8689-4D6A-B151-4DD4BEA85138</gtr:id><gtr:name>Central European Institute of Technology</gtr:name><gtr:address><gtr:line1>Central European Institute of Technology</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A22541F-DA58-481E-8D0C-C4BCF4EA030E"><gtr:id>9A22541F-DA58-481E-8D0C-C4BCF4EA030E</gtr:id><gtr:name>EMBL - European Bioinformatics Institute</gtr:name><gtr:address><gtr:line1>Wellcome Trust Genome Campus</gtr:line1><gtr:line2>Hinxton</gtr:line2><gtr:line4>Cambridge</gtr:line4><gtr:line5>Cambridgeshire</gtr:line5><gtr:postCode>CB10 1SD</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/A8FFE8BD-0636-4C9D-A5F7-29460A47D865"><gtr:id>A8FFE8BD-0636-4C9D-A5F7-29460A47D865</gtr:id><gtr:firstName>Len</gtr:firstName><gtr:surname>Stephens</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/A5455936-4449-4C09-A477-1CF166514A09"><gtr:id>A5455936-4449-4C09-A477-1CF166514A09</gtr:id><gtr:firstName>Nicolas</gtr:firstName><gtr:surname>Le Novere</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FB%2F000C0419"><gtr:id>48FAC953-07C9-49C8-9466-3FF41EB8B7FE</gtr:id><gtr:title>A systems approach to understanding lipid, Ca2+ and MAPK signalling networks</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/B/000C0419</gtr:grantReference><gtr:abstractText>Sensing and interpreting external stimulus often involves the recruitment of several cross-regulating signalling pathways. NLN has been studying for many years the biochemical determinant of neuroadaptation. In the chosen model system, the medium-sized spiny neuron of the striatum (existing and planned uplft grant funded work in the lab of MC are focused on this class of neurons giving us significant mass and focus within the ISP), synaptic plasticity and dendritic remodeling, involve several intracellular kinase-dependent signalling pathways acting with different timescales(131). For instance, CaMKII, PI3K and PKC trigger short-term plasticity in seconds through protein modifications and translocation. PKA, ERK (MAPK) and CaMKIV persistently modulate gene regulatory networks and change gene expression. TrkB, a tyrosine kinase receptor for neurotrophins and PI3K/PKB are also involved in long-term effects on for instance dendritic remodelling and neuronal survival. All these kinase pathways are linked through the activation/inhibition of phosphatases, ultimately forming a network of kinases, phosphatases and substrate phosphoproteins with variable dynamics. However, at present the knowledge of these phosphorylation-dependent signalling pathways remains fragmented and largely descriptive. NLN's activity at the BI will follow two lines. (i) He will continue to study the role of Ca2+ signals in synaptic plasticity, developing highly realistic models and benefiting from Llew Roderick?s (Epigenetcis ISPG) expertise in Ca2+ analysis. Those models will help in understanding the respective roles of the proteins constituting the Ca2+-sensitive, long-term potentiation cycle - glutamate ionotropic receptors, calmodulin, neurogranin, calcineurin and CaMKII ? in decoding amplitude, frequency and duration of Ca2+ signals. A better grasp Ca2+ homeostasis and dynamics is now acknowledged to be a key to understanding synaptic ageing(132, 133). (ii) NLN's group will use synaptic signalling as a model system to understand the mechanisms and consequences of integrating multiple signalling pathways.</gtr:abstractText><gtr:fund><gtr:end>2017-03-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2012-04-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>1314409</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Austrian Academy of Sciences</gtr:collaboratingOrganisation><gtr:country>Austria, Republic of</gtr:country><gtr:department>Research Centre for Molecular Medicine (CeMM)</gtr:department><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>0D57CBB2-CCCB-4CB6-BAE0-E6B5E4848B31</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-7</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centre for Genomic Regulation (CRG)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>100F6394-4D14-4F5F-9D41-A42B49F72B7C</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-2</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Computer Vision and Image Processing (CVIP)</gtr:department><gtr:description>Regulation of signalling through the Ras/ERK pathway by DUSPs</gtr:description><gtr:id>F0603133-64F0-456C-BDBC-228D62FFE1E4</gtr:id><gtr:impact>Too early to assess full impacts - collaboration has only recently started.</gtr:impact><gtr:outcomeId>58c7cc3d3253b5.85855799-1</gtr:outcomeId><gtr:partnerContribution>Stephen Keyse's lab are generating unique DUSP null cell lines and mutant DUSP constructs</gtr:partnerContribution><gtr:piContribution>We are undertaking high content microscopy to assess the impact of ablating expression of dual specificity phosphatases (DUSPs) on spatiotemporal aspects of ERK signalling and resultant cell fate decisions</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bath</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca ERK</gtr:description><gtr:id>68E8EFDB-C62D-4EBD-A2F0-B62D80C50BB6</gtr:id><gtr:impact>Much of this is still early stage. However, high throughput drug screening has identified several drug combinations that markedly transform the growth inhibitory effects of Selumetinib. Our analysis of new resistance models has identified several completely novel potential mechanisms which we are in the process of validating. These studies will lead to further papers in addition those publications already reported and may contribute to the testing of new drug combinations in the clinic in the future.</gtr:impact><gtr:outcomeId>546f6b7e208329.85398167-2</gtr:outcomeId><gtr:partnerContribution>AstraZeneca have performed a variety of Next Gen Seq analyses on samples provided by us to identify genetic and transcriptomic changes associated with resistance; these may be candidate resistance drivers. They are also performing xenograft studies to test specific hypotheses that emerge form our studies.
Our collaborators at the University of Bath are investigating how the magnitude of ERK1/2 signalling can impart different tumour cell responses when Selumetinib is withdrawn from resistant cells. 
In a three-way collaboration between our lab, the CRUK-CI and AstraZeneca we are peforming high throughput drug combination screens to identify drugs that combine with Selumetinib to provide superior tumour growth inhibition or tumour cell death.</gtr:partnerContribution><gtr:piContribution>We want to understand the various mechanisms by which ERK1/2 pathway-addicted tumour cells adapt and acquire resistance to the MEK1/2 inhibtor Selumetinib. We have generated a variety of human tumour cell lines with acquired resistance to the clinical candidate MEK1/2 inhibitor Selumetinib. These include cell lines in which BRAF is the driving oncogene but also those in which KRAS is the driving oncogene. We have analysed the activation state of the ERK1/2 pathway in these cells and in some cases validated the resistance mechanism. In other cases this analysis is ongoing. In some models we find that resistance is reversible upon drug withdrawal suggesting that resistant cells actually have a fitness deficit in the absence of drug. We are investigating the mechanisms that underlie this fitness deficit.
For our partner (AstraZeneca/CRUK) this may allow development of rational strategies to overcome or delay resistance and thereby provide more durable drug responses. For our own basic biological interests this should provide insights into how this key cell fate signalling pathway is regulated; this may be relevant to emerging regenerative medicine protocols.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>CRUK CI ERK pathway</gtr:description><gtr:id>14542DCA-5735-4A6E-B09C-C52F4B6E059B</gtr:id><gtr:impact>Partnership/collaboration still active and ongoing. Major, outputs (publications) still to emerge</gtr:impact><gtr:outcomeId>56c1e06d8b0c12.83269370-1</gtr:outcomeId><gtr:partnerContribution>Our partners are testing some of these drug combinations in 'in vivo' mouse models - a key pre-clinical validation step</gtr:partnerContribution><gtr:piContribution>We have identified mechanisms of innate resistance to MEK inhibitors (MEKi) in human tumour cells. These mechanisms have in turn suggested drug combinations (MEKi + Xi, MEKi +Yi, etc) that should overcome innate resistance to MEK inhibitors allowing effect inhibition of the growth of tumor cells. We have tested these combinations in dozens of human cancer cell lines. The data is robust and merits further investigation, including validation in 'in vivo' mouse models</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:department>Biotech Research and Innovation Center (BRIC)</gtr:department><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>B86884AD-48B6-4BCA-B339-925DAD05AC34</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-12</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Helmholtz Association of German Research Centres</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>The Max Delbr?ck Center for Molecular Medicine (MDC)</gtr:department><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>489EBC67-056C-4FF4-9311-5BA643F7F375</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-5</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca mTOR</gtr:description><gtr:id>2093D21D-6034-4672-B235-9C770AB9F320</gtr:id><gtr:impact>The PhD student successfully completed their PhD, two papers have been published and additional work is ongoing.</gtr:impact><gtr:outcomeId>56c340cc59ad52.32361337-1</gtr:outcomeId><gtr:partnerContribution>Our partners at AstraZeneca part funded a BBSRC PhD student to do this work, provided large quantities of mTOR inhibtor as an 'in kind' contribution and performed next gen sequencing and other analyses of resistant cells to probe for mechanisms of resistance</gtr:partnerContribution><gtr:piContribution>Inhibitors of mTOR promote healthy lifespan extension in model organisms by promoting autophagy and are also undergoing evaluation as a treatment for cancer. However, complete mTOR inhibition is not compatible with life. We are interested in how the mTOR pathway is remodelled during chronic exposure to mTOR inhibitors. We have generated cells that are resistant to mTOR inhibitors and examined the mTOR pathway to identify changes that underpin resistance.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Friedrich Miescher Institute for Biomedical Research (FMI)</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>5ABCEA3D-9956-4B54-8D40-4FB634737C8D</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-1</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>EMBL European Bioinformatics Institute (EMBL - EBI)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Saez-Rodriguez ERK</gtr:description><gtr:id>68D8299D-C6B1-4451-BEC9-7F37A164481D</gtr:id><gtr:impact>A review article has been published and a primary research paper is in preparation and will certainly lead to additional outputs</gtr:impact><gtr:outcomeId>56c202a35ed1c2.02577968-1</gtr:outcomeId><gtr:partnerContribution>Our partners have provided bioinformatics support and training to a PhD student who was embedded in the partner group at the EBI. This included network analysis and gene set enrichment analysis. It led to some completely new insights into how ERK1/2 signalling controls cell cycle arrest/senescence</gtr:partnerContribution><gtr:piContribution>We have generated gene expression data sets from cells exhibiting different levels of ERK1/2 signalling that drive different cell fates - cell proliferation or cell cycle arrest &amp;amp; senescence.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Netherlands Cancer Institute (NKI)</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>5ED93597-3BDE-4DA0-89C1-A78F4DF7ED81</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-10</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vlaams Instituut Biotechnologie (VIB)</gtr:collaboratingOrganisation><gtr:country>Belgium, Kingdom of</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>B95445B2-39F8-4EA4-8CE5-6E663AB1CE5F</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-3</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Institute of Oncology (IEO)</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>DCA1DA6C-D0AE-4CDA-96A7-DDBA54FD49A0</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-8</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Tromso</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Department of Medical Biology</gtr:department><gtr:description>p62 phosphorylation</gtr:description><gtr:id>F78C63A1-42F2-40AF-B5E7-3EC09407F2CE</gtr:id><gtr:impact>Too soon for any specific outputs as the collaboration has only just started. However, i have visited the University of Tromso and presented two Lectures as part of a PhD training course</gtr:impact><gtr:outcomeId>58c6c504963577.81484997-1</gtr:outcomeId><gtr:partnerContribution>Terje Johansen's lab will share reagents and expertise and perform specific experiments to define the interaction between DYRKs and p62</gtr:partnerContribution><gtr:piContribution>Sharing of data; discussion of new experimental directions; experiments
We have identified p62/SQSTM1 as a novel substrate of DYRK1B and DYRK2. We are investigating the role of this phosphorylation on p62 functions in proteostasis, stress responses and nutrient signalling</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2017-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Institute for Molecular Medicine Finland</gtr:collaboratingOrganisation><gtr:country>Finland, Republic of</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>E1389D96-5C40-4B8E-80B4-310E5D291D7B</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-11</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Central European Institute of Technology (CEITEC)</gtr:collaboratingOrganisation><gtr:country>Czech Republic</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>71625A0C-72FC-4E38-BC3F-E6A34D82EA3F</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-9</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Curie Institute Paris (Institut Curie)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>40141D0F-0CE2-432B-ADB1-010F58489754</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-4</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Division of Biosciences</gtr:department><gtr:description>Nick Luscombe</gtr:description><gtr:id>E9DF8DD2-97D3-4156-8965-AAE070097750</gtr:id><gtr:impact>Publications, a number are on-going. Multi-disciplinary, biochemistry, computer modelling, bioinformatics, biological chemistry/mass spec development.</gtr:impact><gtr:outcomeId>546373be5e37e1.52808872-1</gtr:outcomeId><gtr:partnerContribution>Training in bioinformatic techniques</gtr:partnerContribution><gtr:piContribution>We provided data, knowledge and experience</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca ERK</gtr:description><gtr:id>29D01030-8776-461D-9D8E-6F5F596073E1</gtr:id><gtr:impact>Much of this is still early stage. However, high throughput drug screening has identified several drug combinations that markedly transform the growth inhibitory effects of Selumetinib. Our analysis of new resistance models has identified several completely novel potential mechanisms which we are in the process of validating. These studies will lead to further papers in addition those publications already reported and may contribute to the testing of new drug combinations in the clinic in the future.</gtr:impact><gtr:outcomeId>546f6b7e208329.85398167-1</gtr:outcomeId><gtr:partnerContribution>AstraZeneca have performed a variety of Next Gen Seq analyses on samples provided by us to identify genetic and transcriptomic changes associated with resistance; these may be candidate resistance drivers. They are also performing xenograft studies to test specific hypotheses that emerge form our studies.
Our collaborators at the University of Bath are investigating how the magnitude of ERK1/2 signalling can impart different tumour cell responses when Selumetinib is withdrawn from resistant cells. 
In a three-way collaboration between our lab, the CRUK-CI and AstraZeneca we are peforming high throughput drug combination screens to identify drugs that combine with Selumetinib to provide superior tumour growth inhibition or tumour cell death.</gtr:partnerContribution><gtr:piContribution>We want to understand the various mechanisms by which ERK1/2 pathway-addicted tumour cells adapt and acquire resistance to the MEK1/2 inhibtor Selumetinib. We have generated a variety of human tumour cell lines with acquired resistance to the clinical candidate MEK1/2 inhibitor Selumetinib. These include cell lines in which BRAF is the driving oncogene but also those in which KRAS is the driving oncogene. We have analysed the activation state of the ERK1/2 pathway in these cells and in some cases validated the resistance mechanism. In other cases this analysis is ongoing. In some models we find that resistance is reversible upon drug withdrawal suggesting that resistant cells actually have a fitness deficit in the absence of drug. We are investigating the mechanisms that underlie this fitness deficit.
For our partner (AstraZeneca/CRUK) this may allow development of rational strategies to overcome or delay resistance and thereby provide more durable drug responses. For our own basic biological interests this should provide insights into how this key cell fate signalling pathway is regulated; this may be relevant to emerging regenerative medicine protocols.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca ERK</gtr:description><gtr:id>613C915A-970E-43EB-B4EE-F65F72612AF3</gtr:id><gtr:impact>Much of this is still early stage. However, high throughput drug screening has identified several drug combinations that markedly transform the growth inhibitory effects of Selumetinib. Our analysis of new resistance models has identified several completely novel potential mechanisms which we are in the process of validating. These studies will lead to further papers in addition those publications already reported and may contribute to the testing of new drug combinations in the clinic in the future.</gtr:impact><gtr:outcomeId>546f6b7e208329.85398167-3</gtr:outcomeId><gtr:partnerContribution>AstraZeneca have performed a variety of Next Gen Seq analyses on samples provided by us to identify genetic and transcriptomic changes associated with resistance; these may be candidate resistance drivers. They are also performing xenograft studies to test specific hypotheses that emerge form our studies.
Our collaborators at the University of Bath are investigating how the magnitude of ERK1/2 signalling can impart different tumour cell responses when Selumetinib is withdrawn from resistant cells. 
In a three-way collaboration between our lab, the CRUK-CI and AstraZeneca we are peforming high throughput drug combination screens to identify drugs that combine with Selumetinib to provide superior tumour growth inhibition or tumour cell death.</gtr:partnerContribution><gtr:piContribution>We want to understand the various mechanisms by which ERK1/2 pathway-addicted tumour cells adapt and acquire resistance to the MEK1/2 inhibtor Selumetinib. We have generated a variety of human tumour cell lines with acquired resistance to the clinical candidate MEK1/2 inhibitor Selumetinib. These include cell lines in which BRAF is the driving oncogene but also those in which KRAS is the driving oncogene. We have analysed the activation state of the ERK1/2 pathway in these cells and in some cases validated the resistance mechanism. In other cases this analysis is ongoing. In some models we find that resistance is reversible upon drug withdrawal suggesting that resistant cells actually have a fitness deficit in the absence of drug. We are investigating the mechanisms that underlie this fitness deficit.
For our partner (AstraZeneca/CRUK) this may allow development of rational strategies to overcome or delay resistance and thereby provide more durable drug responses. For our own basic biological interests this should provide insights into how this key cell fate signalling pathway is regulated; this may be relevant to emerging regenerative medicine protocols.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Museu da Lourinh?</gtr:collaboratingOrganisation><gtr:country>Portugal, Portuguese Republic</gtr:country><gtr:department>Gulbenkian Institute of Science</gtr:department><gtr:description>EU LIFE Translational Research</gtr:description><gtr:id>0A37772A-CA4B-4D6A-A39C-B564E511AF38</gtr:id><gtr:impact>One policy paper on promoting translational research in the EU. 3 scientific meetings have been arranged so far. Other impacts are anticipated</gtr:impact><gtr:outcomeId>56c2ee836840a2.42675146-6</gtr:outcomeId><gtr:partnerContribution>The EU LIFE Translational Research Working Group works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:partnerContribution><gtr:piContribution>Babraham is part of the EU LIFE Alliance of 13 top european life science institutes which collaborate in various areas to support and strengthen European research excellence. The BI Head of Knowledge Exchange &amp;amp; Commercialisation is a group leader in the Signalling Programme and represents BI on the Translational Research Working Group. This WG works together to share best practice, promote collaborations, arrange EU LIFE scientific meetings and write policy papers.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>BI School day 2016</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>17BE160D-54F7-49FE-AB64-D4F7958B937F</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>58bda96d0cec17.16218417</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>BI School day 2015</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A23841BC-9009-4D45-AEC5-A1483EA1BA59</gtr:id><gtr:impact>10 of the pupils attending the Babraham Institute school day visited my lab. We gave them presentations and practicals on building and analysing networks. This included activities with Haribos and toothpicks, as well as computer based tutorials (using the software Cytoscape)</gtr:impact><gtr:outcomeId>56c1be295c5b89.61079513</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Teaching Networks and Pathways, Cambridge Universtity Part III Systems Biology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>78E38613-0FD6-43B3-8F1E-B85FB773B90F</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>58bda9277bde71.62244663</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Introduction to Networks - UTC 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>35243B04-7C7F-40AA-9956-2D63EF3CD788</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>58bda8e3b90229.40170383</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Open Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4DCDA98E-DAAE-4464-9809-929F4D061FA6</gtr:id><gtr:impact>Students visited the lab and undertook small lab-based proejcts supervised by students/post-docs and myself. I explained the research that we do and discussed ethical issues such as the use of animals in research.
This precipitated excellent discussion and dialogue.

We received excellent feedback from the schools involved and requests for further outreach activities</gtr:impact><gtr:outcomeId>546f1146bc7243.35670753</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Teaching Networks and Pathways, Cambridge Universtity Part III Systems Biology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>31A34A23-5AB7-4515-BAEB-741FAB23237E</gtr:id><gtr:impact>Around 40 students of the Cambridge University Part III Systems Biology attended my course on Networks and biochemical pathways. The course was accompanied by a tutorials on reconstructing and analysing networks as well as a journal club, where students analysed relevant publications.</gtr:impact><gtr:outcomeId>56c1c823f165c7.85752036</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Teaching modelling at Gebze Technical University</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>60E74743-AA38-4B2C-9A95-483ED77D19A3</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>58bdaa18b12684.15749895</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description> BI School day 2017</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2E8BC3CD-F083-4120-B7B8-9D68CE208554</gtr:id><gtr:impact>NA</gtr:impact><gtr:outcomeId>58bda9a0299f37.82799386</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Computational Modeling in Biology Network</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>62F47F1C-0D1D-4BA1-85C0-EF50358BB1E3</gtr:id><gtr:impact>I created COMBINE to coordinate the development of standards in computational systems biology. The initiative includes several workshops a year (discussion of future standards, implementation of current standards, and end-user training), diffusion lists, social media dissemination.</gtr:impact><gtr:outcomeId>56c1c94f8b3f73.57005686</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://co.mbine.org</gtr:url><gtr:year>2011,2012,2013,2014,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Introduction to Networks - UTC 2015</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>59F45D8B-8334-4475-86F5-7AEC076A3397</gtr:id><gtr:impact>I presented the notion of networks, their ubiquity, how to analyse their structure. I then focused on biological networks, their importance, how to reconstruct and analyse them.</gtr:impact><gtr:outcomeId>56c1c709881e77.91196624</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ISCB Community of Special Interest &quot;SysMod&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B92496CD-F0B5-443C-9897-B18F2A08C619</gtr:id><gtr:impact>Recently, advances in genomics have caused bioinformatics and systems biology modeling to converge. For example, systems modeling has become more reliant on bioinformatic network inference to build models and has begun to use transcriptomics and proteomics data to train models. More communication between systems modelers and bioinformaticians is needed to further integrate these fields. In particular, more communication between systems modellers and bioinformaticians is needed to build models of whole cells, organs and organisms. The Computational Modeling of Biological Systems (SysMod) Community Of Special Interest aims at bridging the gap. Its first activity is the organisation of a Special Interest Group symposium at the annual bioinformatics conference (ISMB).</gtr:impact><gtr:outcomeId>56c1cad0b25983.43802693</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://sysmod.info</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public feedback exercise</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1BB4AE9B-9BC1-4778-8C4C-50AEB928D328</gtr:id><gtr:impact>The Signalling Department, in parallel with other BI departments, presented our research to a professionally selected sample of the UK public with the interntion of gaining public feedback on our institute and research.</gtr:impact><gtr:outcomeId>56b883af3884f0.51484512</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visits by Teachers</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>962AC896-DD68-424A-A33A-9EAFFC915980</gtr:id><gtr:impact>I hosted two 6th form Biology teachers (one PhD trained, the other MSc trained) who were visiting my Institution during Half Term to update their knowledge as part of their CPD</gtr:impact><gtr:outcomeId>56c1e8c3788c99.07519338</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>1) We have shown that different perturbations of phosphoinositide signalling triggered large modifications of the transcriptome in human cells. The responses to phosphoinositides sensitive to epidermal growth factor stimulations are more involved in &amp;quot;dynamic&amp;quot; processes (cell migration, wound healing) while the responses insensitive to epidermal growth factor are more involved in &amp;quot;static&amp;quot; processes (cell adhesion, extracellular matrix). We identified Blimp1 as a key transcription factor mediating the former effects. A large proportion of the genes modified by phosphoinotitide signalling perturbations via Blimp1 code for proteins involved in phosphoinotitide signalling itself, revealing a transcriptional feedback loop.

2) We developed a new model of calmodulin, with hemiconcerted conformational switching, which allowed us to understand the observed effects of the synaptic protein Neurogranin on Calmodulin responses to calcium (Lai et al PloS Comput Biol, 2015). Integrating Neurogranin, our existing models of Calcium/Calmodulin Kinase II and a new model of Calcineurin, we showed why Neurogranin controls the basal sensitivity of the synapse to calcium perturbations rather than the dynamic range of the responses, as proposed before.

3) We studied the effect of calcium signalling on diffusion and internalisation of glutamate NMDA receptors, and therefore on synaptic plasticity. In order to investigate the impact of amyloid beta on synaptic function, we incorporated Pyk2/Fyn and Calcineurin/STEP pathways to the model of calicum signalling. The simulations explain the biphasic effect observed after amyloid beta treatment in animal models, with a transient increase of synaptic receptors followed by a long term decrease. These models of synaptic signalling are integrated with models of amyloid beta aggregation in order to provide a multi-scale view of Alzheimer's Disease impact over the lifetime of a population of patients.

3) Using a model incorporating signalling cascades - including MAPK - and gene regulatory networks, we reproduced the observed epigenetics barrier between embryonic and trophoblast stems cells. The initial models, validated against experimental measurement, predicted new perturbations to overcome the barrier such as block of the Stat3 signalling. These predictions are now being tested.

4) To support our modelling activity, we further developed key software tools, such as the JSBML software library, the Systems Biology Format Converter, and standards to encode model and simulation descriptions. These tools benefit the community of systems biology at large, and are well recognised and used in the field.</gtr:description><gtr:exploitationPathways>A quantitative description of the dynamics of signalling pathways is key to understand their function, predict the effect of perturbations and develop drugs. Our models are provided in standard formats through public repository so that others can re-use and build on them.</gtr:exploitationPathways><gtr:id>858A893E-DBE4-4108-AD97-88CB40777D28</gtr:id><gtr:outcomeId>56d6b7e4dab677.16685327</gtr:outcomeId><gtr:sectors><gtr:sector>Education,Healthcare,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of Scientific Advisory Board of Cancer Research Technology Discovery Lab</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FC434D5D-0E87-48ED-8AB4-2C8CCDB90C97</gtr:id><gtr:outcomeId>58c7ba68ae98d8.97108955</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Scientific advisor to the Research Data Alliance</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>556467C9-2A7A-421F-A75A-1D0BF6D6B147</gtr:id><gtr:outcomeId>56bb43de035207.21098864</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Advisor to Science Europe on multi-disciplinarity career paths</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>D62FED40-5FF4-4778-9CA4-B89AE6E2DA49</gtr:id><gtr:outcomeId>56bb451404cd34.65416426</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>RNA-seq data set derived from HEK293 cells which exhibit Tet-regulated DYRK1B expression
Reports genome wide changes in abundance and splicing patterns in response to DYRK1B expression</gtr:description><gtr:id>EB26679C-EBC0-4B56-90FF-DBBC8F9947FC</gtr:id><gtr:impact>Too soon for impacts. Data currently being analsyed</gtr:impact><gtr:outcomeId>58c7a59800f722.99170452</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DYRK1B transcriptome gene data set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Human Illumina bead array describing changes in transcriptome associated with ERK-driven cell cycle arrest/senescence</gtr:description><gtr:id>D952202E-DAE4-44D8-BFCD-603E237F5764</gtr:id><gtr:impact>New insights into ERK signalling associated with cell cycle arrest and senescence
Identification of new links between ERK signalling the cell cycle
Identification of ERK target genes</gtr:impact><gtr:outcomeId>58c6cd30235b25.97893267</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ERK pathway cell cycle arrest/senescence gene data set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>All the RNA-Seq data from the publication Kiselev V.Y., Juvin V., Mouhannad M., Luscombe N.M., Hawkins P., Le Nov&amp;egrave;re N., Stephens L.R. Perturbations of PIP3 signalling trigger a global remodelling of mRNA landscape and reveal a transcriptional feedback loop. Nucleic Acids Research (2015) 43 (20): 9663-9679</gtr:description><gtr:id>C50E13C1-2666-4C24-BE8F-DBBD3BC76C02</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>56bb36e2d8d1c9.01419847</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>RNA-Seq from Kiselev et al</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69822</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>RNA-seq data set derived from HEK293 cells which exhibit Tet-regulated DYRK2 expression
Reports genome wide changes in abundance and splicing patterns in response to DYRK2 expression</gtr:description><gtr:id>47D74B2E-B0B3-49F3-BF20-693DC3CB73E1</gtr:id><gtr:impact>Too soon for impacts. Data currently being analysed</gtr:impact><gtr:outcomeId>58c7a5eaba2e09.54170308</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>DYRK2 Transcriptome gene data set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Human Illumina bead array descricing genome-wide changes in mRNA expression in parental and MEKi resistant cells</gtr:description><gtr:id>AF4A07D2-58AB-47F4-B7B7-14B666C2CA20</gtr:id><gtr:impact>One primary research paper and review articles. Demonstration of mechanism by which tumour cells acquire resistance to MEK inhibitors</gtr:impact><gtr:outcomeId>56c34f401f6057.07459789</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>MEKi resistance gene set</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>Human Illumina bead array data for comparison of differences in gene expression between parental and FGFRi-resistant KMS11 cells. Referecne paper
Chell et al (2013) Oncogene. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance</gtr:description><gtr:id>E5D0F4BB-EF49-497E-8C68-07916717359A</gtr:id><gtr:impact>Data contributed to a primary research paper and helped to define the first reported mechanism of acquired resistance to FGFR inhibitors</gtr:impact><gtr:outcomeId>56c34d65e9d019.02593465</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Illumina mRNA dataset FGFRi</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.ebi.ac.uk/arrayexpress/experiments/E-TABM-1222/</gtr:url></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>An R package containing all datasets, and scripts/functions needed to reproduce them, from the work described in the publication Kiselev V.Y., Juvin V., Mouhannad M., Luscombe N.M., Hawkins P., Le Nov&amp;egrave;re N., Stephens L.R. Perturbations of PIP3 signalling trigger a global remodelling of mRNA landscape and reveal a transcriptional feedback loop. Nucleic Acids Research (2015) 43 (20): 9663-9679</gtr:description><gtr:id>05F38BFF-8016-48A8-957C-F71F09D59914</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>56bb367e8e2041.33825357</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Kiselev et al PIP3 project</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>https://github.com/wikiselev/rnaseq.mcf10a</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput><gtr:researchDatabaseAndModelOutput><gtr:description>BioModels Database is a free and open-source repository for storing, exchanging and retrieving quantitative models of biological interest. All the models in the curated section of BioModels Database have been described in peer-reviewed scientific literature.

The models stored in the curated branch of BioModels Database are compliant with MIRIAM, the standard of model curation and annotation. The models have been simulated by curators to check that when run in simulations, they provide the same results as described in the publication. Model components are annotated, so the users can conveniently identify each model element and retrieve further information from other resources.</gtr:description><gtr:id>F6C6AEBE-7FA9-4972-AB1F-56F674CD6C76</gtr:id><gtr:impact>BioModels Database has become a worldwide reference resource for systems biology. It is being used by the community in a variety of ways; People search for existing models, to learn about systems' behaviours, or to developer new models. The resource is also used to benchmark different simulation systems, and to study the clustering of models based upon their annotations. Model deposition to the database today is advised by several publishers of scientific journals.</gtr:impact><gtr:outcomeId>5460d87d739222.35883691</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>BioModels</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:url>http://www.ebi.ac.uk/biomodels</gtr:url></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have generated gastric, breast and myeloma cells with acquired resistance to AZD4547, an FGFR inhibitor undergoing clinical evaluation, and a second closely related molecule.
We have now performed genome-wide gene expression, exome sequencing and phospho-proteomics analysis on parental and resistant cells.</gtr:description><gtr:id>A676399F-3408-407B-97A1-7BF7B0AA71A4</gtr:id><gtr:impact>We have generated a host of new information on genetic, transcriptomic and biochemical changes associated with acquired resistance to these drugs. We are currently mining this information and testing specific gene products as candidate drivers of resistance. This information is being shared with project partners.
This data will be made freely available as each study is published allowing other researchers to access and benefit from our datasets</gtr:impact><gtr:outcomeId>546ef1df2dc760.07420463</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>FGFRi resistant cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated HCT116 cell liens in which we have deleted the RNA binding proteins ZFP36L1 or ZFP36L2 - singly or in combination (DKO) using CRISPR/Cas9 gene editing.</gtr:description><gtr:id>923C0030-8051-4470-84D6-37D0D7B93694</gtr:id><gtr:impact>ZFP36L1 KO cells featured in our 2016 manuscript - Galloway et al Science
Further impacts will arise as we undertake further characterisation of these cell lines
These will be made available to the community in the future</gtr:impact><gtr:outcomeId>58c7a6fb607720.07920877</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ZFP36 KO cell llines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated HCT116 cell lines lacking one or other or both (DKO) of the critical NFkB activating protein kinases IKKalpha or IKKbeta using CRISPR/Cas9 gene targeting.</gtr:description><gtr:id>5803F839-BE1B-44EB-B866-BD11B907916B</gtr:id><gtr:impact>Too early for impacts; cells still being charatcerised.
These will be made available to the community in the future</gtr:impact><gtr:outcomeId>58c7a9eca0fa27.74525116</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>IKKalpha and IKKbeta KO cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated human cell lines (cancer cells and primary human fibroblasts) with adaptive resistance to the mTOR inhibitors rapamycin and AZD8055</gtr:description><gtr:id>63A6A362-2E92-454D-807D-94F97C2D9798</gtr:id><gtr:impact>Two papers have been published and this has provided insight in to likely mechanisms by which cancer cells may adapt and acquire resistance to mTOR inhibitors</gtr:impact><gtr:outcomeId>56c34733c8e629.16611224</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>mTORi resistant cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated a panel of colorectal cancer cell lines (BRAFmut or KRASmut) with acquired resistance to the MEK inhibitor Selumetinib.</gtr:description><gtr:id>582ECAA4-EEB5-405A-899D-DE286FDAF65F</gtr:id><gtr:impact>We have generated a host of new information on genetic, transcriptomic and biochemical changes associated with acquired resistance to these drugs. We are currently mining this information and testing specific gene products as candidate drivers of resistance. This information is being shared with project partners</gtr:impact><gtr:outcomeId>548ea7109d2299.72714102</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MEKi resistant tumour cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have used CRISPR/Cas9 gene editing to generate COLO205 cell line clones lacking the CDK inhibitor p57KIP2 encoded by CDKN1C</gtr:description><gtr:id>D210476E-62B9-4F44-96AE-F596F690A9A7</gtr:id><gtr:impact>We have used these celsl to demonstrate the role of p57KIP2 in ERK-driven cell cycle arrest. This will form part of a future manuscript.
Additional impacts will emerge as we undertake further analysis
These will be made available to the community in the future</gtr:impact><gtr:outcomeId>58c7a7a5489ed9.29149329</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>CDKN1C/p57KIP2 KO cell lines</gtr:title><gtr:type>Cell line</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>The Systems Biology Format Converter (SBFC) aims to provide a generic framework to convert a Systems Biology model format into another. Interoperability between formats is a recurring issue in Systems Biology.</gtr:description><gtr:id>A516EB76-857E-421B-8709-3D53C3D4649B</gtr:id><gtr:impact>Systems Biology software and databases can use a single conversion system to import and export a variety of formats.</gtr:impact><gtr:outcomeId>56bb1370cd5c12.67503458</gtr:outcomeId><gtr:title>Systems Biology Format Converter</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://sbfc.sourceforge.net/mediawiki/index.php/Main_Page</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>JSBML is a community-driven project to create a free, open-source, pure Java library for reading, writing, and manipulating SBML files and data streams.</gtr:description><gtr:id>04D4F1E6-4098-44EC-8825-048A3B9D8156</gtr:id><gtr:impact>Software and database developed in Java can now use a native library to read and write mathematical models encoded in SBML, the most used format in systems biology.</gtr:impact><gtr:outcomeId>56bb12f6405674.25026189</gtr:outcomeId><gtr:title>JSBML</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://sbml.org/Software/JSBML</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>The Mathematical Modelling Ontology (MAMO) is a classification of the types of mathematical models used in the life sciences (for the time being), the type of variables they use, the readout that can be expected and other relevant features.</gtr:description><gtr:id>5D3BC2F5-A74D-4F3C-A498-616D5D1032F5</gtr:id><gtr:impact>MAMO is used to annotate mathematical models in systems biology</gtr:impact><gtr:outcomeId>56bb16bf52fb82.38144528</gtr:outcomeId><gtr:title>Mathematical Modelling Ontology</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://co.mbine.org/standards/MAMO</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>This package contains a collection of pipelines for dynamic modelling of biological systems. It aims to automate common processes and speed up productivity for tasks such as model simulation, single and double parameter scan, and parameter estimation.</gtr:description><gtr:id>ECEC6B08-0FE4-46F7-90A4-3C64EC1A8C27</gtr:id><gtr:impact>Streamlined model identifiability and parameter estimation in systems biology modelling.</gtr:impact><gtr:outcomeId>58bda42e26a5e2.05411214</gtr:outcomeId><gtr:title>SBpipe</gtr:title><gtr:type>Software</gtr:type><gtr:url>https://pdp10.github.io/sbpipe/</gtr:url><gtr:yearFirstProvided>2017</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B36F3C02-7778-4E09-8341-9C25033749F0</gtr:id><gtr:title>Enabling surface dependent diffusion in spatial simulations using Smoldyn.</gtr:title><gtr:parentPublicationTitle>BMC research notes</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ce624399c334da393d31654d2e6d70b"><gtr:id>5ce624399c334da393d31654d2e6d70b</gtr:id><gtr:otherNames>Seeliger C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1756-0500</gtr:issn><gtr:outcomeId>56bb0f300d3061.92716773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94162D85-49D3-4594-9502-0D21D8B0A9DD</gtr:id><gtr:title>Epigenetic memory of the first cell fate decision prevents complete ES cell reprogramming into trophoblast.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cfc36c842c43f3126416dda699d912d5"><gtr:id>cfc36c842c43f3126416dda699d912d5</gtr:id><gtr:otherNames>Cambuli F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>548ea55ae82737.45621464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CC8BA2AA-D036-4827-BC86-5C2D259734FE</gtr:id><gtr:title>SBOL Visual: A Graphical Language for Genetic Designs.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c961cd8d0a262ae9dec0799bd73b292"><gtr:id>9c961cd8d0a262ae9dec0799bd73b292</gtr:id><gtr:otherNames>Quinn JY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>56bb0f2c887359.06152404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>35A95C5A-5C67-4D43-A883-40A11E2591FC</gtr:id><gtr:title>That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04fa2c0e92ddbd2d617abc0a02bdeb94"><gtr:id>04fa2c0e92ddbd2d617abc0a02bdeb94</gtr:id><gtr:otherNames>Sale MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>546f5057377115.23896403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2543AA75-897C-4A3B-AA95-3A07B5BCFF4A</gtr:id><gtr:title>Finding our way through phenotypes.</gtr:title><gtr:parentPublicationTitle>PLoS biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/375031ea7f9ffc35719a2a8dd9a04e67"><gtr:id>375031ea7f9ffc35719a2a8dd9a04e67</gtr:id><gtr:otherNames>Deans AR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1544-9173</gtr:issn><gtr:outcomeId>56bb0f2e029844.64618407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F344E2B-990D-46AE-B4FD-56E11E847D03</gtr:id><gtr:title>SynSysNet: integration of experimental data on synaptic protein-protein interactions with drug-target relations.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51c5c35f301373251f5633c9f52c2df0"><gtr:id>51c5c35f301373251f5633c9f52c2df0</gtr:id><gtr:otherNames>von Eichborn J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>542eb9a8d7ef53.05918575</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17625909-056C-40E3-AF90-197F5244A412</gtr:id><gtr:title>Ligand-dependent opening of the multiple AMPA receptor conductance states: a concerted model.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a0e63ee48b00759a96aa11af359a8d4d"><gtr:id>a0e63ee48b00759a96aa11af359a8d4d</gtr:id><gtr:otherNames>Dutta-Roy R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56bb0f2fdb8846.57475610</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87C9AFB0-015B-4226-A793-54FFE97E4A57</gtr:id><gtr:title>CDK1, not ERK1/2 or ERK5, is required for mitotic phosphorylation of BIMEL.</gtr:title><gtr:parentPublicationTitle>Cellular signalling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262698bd2c49ee0e8ffdae19911d01"><gtr:id>78262698bd2c49ee0e8ffdae19911d01</gtr:id><gtr:otherNames>Gilley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0898-6568</gtr:issn><gtr:outcomeId>546f51089a20b5.37391864</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10B1A1AF-51B9-4711-AB55-64514B7FDBE4</gtr:id><gtr:title>The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04fa2c0e92ddbd2d617abc0a02bdeb94"><gtr:id>04fa2c0e92ddbd2d617abc0a02bdeb94</gtr:id><gtr:otherNames>Sale MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>546f5057103fb2.10428686</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E908F6CC-C1C5-4917-A47A-1FE5B41F41B0</gtr:id><gtr:title>Path2Models: large-scale generation of computational models from biochemical pathway maps.</gtr:title><gtr:parentPublicationTitle>BMC systems biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5074802c44c908644b08c9a0fb3725eb"><gtr:id>5074802c44c908644b08c9a0fb3725eb</gtr:id><gtr:otherNames>B?chel F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1752-0509</gtr:issn><gtr:outcomeId>54648e8987b746.19232846</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C6EE6110-2456-4938-BCFC-057B624656A9</gtr:id><gtr:title>SBpipe: a collection of pipelines for automating repetitive simulation and analysis tasks.</gtr:title><gtr:parentPublicationTitle>BMC systems biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6953b105e8ca9f6ef774b9e60d243ee8"><gtr:id>6953b105e8ca9f6ef774b9e60d243ee8</gtr:id><gtr:otherNames>Dalle Pezze P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1752-0509</gtr:issn><gtr:outcomeId>58bd988cdbd386.42714579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AD2699CE-9BF8-45A9-8687-E9B8003C8F5E</gtr:id><gtr:title>Visualization of Endogenous ERK1/2 in Cells with a Bioorthogonal Covalent Probe.</gtr:title><gtr:parentPublicationTitle>Bioconjugate chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/909e68dd43861b9c25e710cddcbfce2e"><gtr:id>909e68dd43861b9c25e710cddcbfce2e</gtr:id><gtr:otherNames>Sipthorp J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1043-1802</gtr:issn><gtr:outcomeId>5aa6aa1d7a7997.74707885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D1F9A5F1-E8CE-49C9-B2AF-A557956BFAE9</gtr:id><gtr:title>Reciprocal regulation of ARPP-16 by PKA and MAST3 kinases provides a cAMP-regulated switch in protein phosphatase 2A inhibition.</gtr:title><gtr:parentPublicationTitle>eLife</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8f54dd2a41646a64a205e3b9cc14946"><gtr:id>c8f54dd2a41646a64a205e3b9cc14946</gtr:id><gtr:otherNames>Musante V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2050-084X</gtr:issn><gtr:outcomeId>5a2fcea8e4c873.27788486</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71630FBC-45C1-4A83-A19B-D740EBFDDE7B</gtr:id><gtr:title>Cooperativity of allosteric receptors.</gtr:title><gtr:parentPublicationTitle>Journal of molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/99f74c996eae4ff77b0b9a95dc1d8832"><gtr:id>99f74c996eae4ff77b0b9a95dc1d8832</gtr:id><gtr:otherNames>Edelstein SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-2836</gtr:issn><gtr:outcomeId>54648e8a0e6a59.86429802</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DF333C2-7F55-4130-B581-05B4AC934F03</gtr:id><gtr:title>MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c4e408dbf8f9d90183ed694ebfa36a55"><gtr:id>c4e408dbf8f9d90183ed694ebfa36a55</gtr:id><gtr:otherNames>Caunt CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>56e7e6b31d8c11.15665849</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>093B4D78-4FDB-42CC-A23D-22A2D10D7364</gtr:id><gtr:title>Control of cell death and mitochondrial fission by ERK1/2 MAP kinase signalling.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d9a51fb590ce42722d2925380aa98f5"><gtr:id>3d9a51fb590ce42722d2925380aa98f5</gtr:id><gtr:otherNames>Cook SJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>5a2faee6dec678.71936775</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D46638C5-15D6-4815-9090-6535F1516449</gtr:id><gtr:title>Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.</gtr:title><gtr:parentPublicationTitle>Cell cycle (Georgetown, Tex.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aa64c866dd997fe62bf344fb5f87e0de"><gtr:id>aa64c866dd997fe62bf344fb5f87e0de</gtr:id><gtr:otherNames>Lochhead PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1551-4005</gtr:issn><gtr:outcomeId>56e1278895d507.35973881</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EB0FDF9-690C-4DEC-A34D-3C16F0EE33BD</gtr:id><gtr:title>De-RSKing ERK - regulation of ERK1/2-RSK dissociation by phosphorylation within a disordered motif.</gtr:title><gtr:parentPublicationTitle>The FEBS journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f30e607a2f14029f1decfbd34338e74a"><gtr:id>f30e607a2f14029f1decfbd34338e74a</gtr:id><gtr:otherNames>Kidger AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1742-464X</gtr:issn><gtr:outcomeId>5aa6aa1d0f3752.82694685</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0026FF9A-1F39-4BBB-B2AA-915719FB8BF6</gtr:id><gtr:title>The Impact of Mathematical Modeling in Understanding the Mechanisms Underlying Neurodegeneration: Evolving Dimensions and Future Directions.</gtr:title><gtr:parentPublicationTitle>CPT: pharmacometrics &amp; systems pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cdd1d56f451adb37f20f9dc0eeaf9f0f"><gtr:id>cdd1d56f451adb37f20f9dc0eeaf9f0f</gtr:id><gtr:otherNames>Lloret-Villas A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2163-8306</gtr:issn><gtr:outcomeId>58bda0c12b5745.13111335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CDF08584-CED4-4C26-9705-3A14DE4DDF50</gtr:id><gtr:title>Adaptation to chronic mTOR inhibition in cancer and in aging.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/78262698bd2c49ee0e8ffdae19911d01"><gtr:id>78262698bd2c49ee0e8ffdae19911d01</gtr:id><gtr:otherNames>Gilley R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>546f51098da9a4.71087295</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BA60BEB5-E0E6-4383-BC88-7DFBC1F353FF</gtr:id><gtr:title>Harmonizing semantic annotations for computational models in biology</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/14799d54b776afc7982d4628d5ad6385"><gtr:id>14799d54b776afc7982d4628d5ad6385</gtr:id><gtr:otherNames>Neal M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:outcomeId>5a957a55d3b7f4.45493624</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA19815B-07E5-42B4-B2B0-63D670AA782B</gtr:id><gtr:title>Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c3a6e5819e23ac730e2fc086c9ece34f"><gtr:id>c3a6e5819e23ac730e2fc086c9ece34f</gtr:id><gtr:otherNames>Chell V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>546f5109671943.32390730</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8431E64D-9AE0-4A89-9787-E3E8CCBC130C</gtr:id><gtr:title>COMBINE archive and OMEX format: one file to share all information to reproduce a modeling project.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2cd6b8bcf7172e04b59d0d04c24d52a6"><gtr:id>2cd6b8bcf7172e04b59d0d04c24d52a6</gtr:id><gtr:otherNames>Bergmann FT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn><gtr:outcomeId>56bb0f3085fc69.34946772</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>59BD6F26-9A36-4255-9802-867894951547</gtr:id><gtr:title>Structure, function, and behaviour of computational models in systems biology.</gtr:title><gtr:parentPublicationTitle>BMC systems biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ccce9c2457ca58c1393a093733661e92"><gtr:id>ccce9c2457ca58c1393a093733661e92</gtr:id><gtr:otherNames>Kn?pfer C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1752-0509</gtr:issn><gtr:outcomeId>54648e8a6996e6.59529467</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E360A7E7-E65C-4841-846C-3F4CDA4256A2</gtr:id><gtr:title>Stimulating translational research: several European life science institutions put their heads together.</gtr:title><gtr:parentPublicationTitle>Trends in molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a8479b792c385ceeaa8f7e0f8f5b7482"><gtr:id>a8479b792c385ceeaa8f7e0f8f5b7482</gtr:id><gtr:otherNames>Bentires-Alj M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-4914</gtr:issn><gtr:outcomeId>56459b1d19cd42.75752579</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AE445A4-E8B1-48D8-B6C5-FCC7ECF0B14E</gtr:id><gtr:title>A community-driven global reconstruction of human metabolism.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed6c52b1e35bc035db7720a4bfa202cd"><gtr:id>ed6c52b1e35bc035db7720a4bfa202cd</gtr:id><gtr:otherNames>Thiele I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>54648e89da0236.19971117</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3F99EAA1-8204-4794-ABDA-1301D08C7DA8</gtr:id><gtr:title>JSBML 1.0: providing a smorgasbord of options to encode systems biology models.</gtr:title><gtr:parentPublicationTitle>Bioinformatics (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56f5713ac7f18b823d9a90722ed664a1"><gtr:id>56f5713ac7f18b823d9a90722ed664a1</gtr:id><gtr:otherNames>Rodriguez N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1367-4803</gtr:issn><gtr:outcomeId>56bb0f2ce84700.04434151</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E98D2800-260D-45F9-805D-1040AC6E0AF6</gtr:id><gtr:title>Cooperative binding.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bf4ab28bb109e6a5ecb9d0980cbdd2a5"><gtr:id>bf4ab28bb109e6a5ecb9d0980cbdd2a5</gtr:id><gtr:otherNames>Stefan MI</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn><gtr:outcomeId>54648e89b06ab3.97826738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>982EFB62-BA23-4323-ABFA-1C0A71F7E5DA</gtr:id><gtr:title>The evolution of standards and data management practices in systems biology.</gtr:title><gtr:parentPublicationTitle>Molecular systems biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/619fab1bee6ea6cafae7e1b9d4b8b44a"><gtr:id>619fab1bee6ea6cafae7e1b9d4b8b44a</gtr:id><gtr:otherNames>Stanford NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1744-4292</gtr:issn><gtr:outcomeId>56bb0f2e60bda7.38341484</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87AA6B1A-5F71-4796-A4EB-0454E2DDAD64</gtr:id><gtr:title>ERK1/2 signalling protects against apoptosis following endoplasmic reticulum stress but cannot provide long-term protection against BAX/BAK-independent cell death.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6729b387bf4e554c2fee167548dc24df"><gtr:id>6729b387bf4e554c2fee167548dc24df</gtr:id><gtr:otherNames>Darling NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>5aa6aa1d4d76d9.20261673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B1B1256-61E9-4490-AA2A-8C7CC903FEA6</gtr:id><gtr:title>Oncogenic K-Ras suppresses IP3-dependent Ca&amp;sup2;? release through remodelling of the isoform composition of IP3Rs and ER luminal Ca&amp;sup2;? levels in colorectal cancer cell lines.</gtr:title><gtr:parentPublicationTitle>Journal of cell science</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/632d617fe4e29c1f8d9be243ac9a776c"><gtr:id>632d617fe4e29c1f8d9be243ac9a776c</gtr:id><gtr:otherNames>Pierro C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9533</gtr:issn><gtr:outcomeId>546f510a662a91.03723586</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C289D97-0198-474F-AE6E-4A8FE0F12F8C</gtr:id><gtr:title>Modulation of calmodulin lobes by different targets: an allosteric model with hemiconcerted conformational transitions.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e0a734460e6495f001a5706569e67a3"><gtr:id>1e0a734460e6495f001a5706569e67a3</gtr:id><gtr:otherNames>Lai M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn><gtr:outcomeId>56bb0f2dcdc0b7.62925434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F7547963-A44E-463E-8C55-D13605473FB1</gtr:id><gtr:title>Intrinsic and acquired resistance to MEK1/2 inhibitors in cancer.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04fa2c0e92ddbd2d617abc0a02bdeb94"><gtr:id>04fa2c0e92ddbd2d617abc0a02bdeb94</gtr:id><gtr:otherNames>Sale MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>546f510a8b7ee3.59910148</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0808CDCF-6321-468F-A9C9-27B04FB14922</gtr:id><gtr:title>Do genome-scale models need exact solvers or clearer standards?</gtr:title><gtr:parentPublicationTitle>Molecular systems biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a333785d5238591cd028eb3dc4fc51ef"><gtr:id>a333785d5238591cd028eb3dc4fc51ef</gtr:id><gtr:otherNames>Ebrahim A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1744-4292</gtr:issn><gtr:outcomeId>56bb0f303191e6.55234644</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B75EF5CE-76B2-4224-B396-F79B1D61719B</gtr:id><gtr:title>Mathematical Models of Pluripotent Stem Cells: At the Dawn of Predictive Regenerative Medicine.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/00adb29a23dfdef44877b9e0fd71243d"><gtr:id>00adb29a23dfdef44877b9e0fd71243d</gtr:id><gtr:otherNames>Pir P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:isbn>978-1-4939-3282-5</gtr:isbn><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>56bb0f2c5f8a86.93023814</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>26FC9D2A-5C22-4910-AB01-53E336951415</gtr:id><gtr:title>The increase in BIK expression following ERK1/2 pathway inhibition is a consequence of G1 cell-cycle arrest and not a direct effect on BIK protein stability.</gtr:title><gtr:parentPublicationTitle>The Biochemical journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04fa2c0e92ddbd2d617abc0a02bdeb94"><gtr:id>04fa2c0e92ddbd2d617abc0a02bdeb94</gtr:id><gtr:otherNames>Sale MJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0264-6021</gtr:issn><gtr:outcomeId>546f505787e4e8.84425750</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>08557AAA-5107-4969-8D27-007028A0F536</gtr:id><gtr:title>The promises of quantitative systems pharmacology modelling for drug&amp;nbsp;development.</gtr:title><gtr:parentPublicationTitle>Computational and structural biotechnology journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/bbf6a674aed960f73bc9527f787939cb"><gtr:id>bbf6a674aed960f73bc9527f787939cb</gtr:id><gtr:otherNames>Knight-Schrijver VR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2001-0370</gtr:issn><gtr:outcomeId>58bda109c570b7.96445602</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64A74E89-3EFD-48AF-90BD-3F546C95319D</gtr:id><gtr:title>Tumour cell responses to MEK1/2 inhibitors: acquired resistance and pathway remodelling.</gtr:title><gtr:parentPublicationTitle>Biochemical Society transactions</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c92f1ca52279657b6aff9f15ffdfcd"><gtr:id>90c92f1ca52279657b6aff9f15ffdfcd</gtr:id><gtr:otherNames>Little AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0300-5127</gtr:issn><gtr:outcomeId>546f510916f0f3.60345414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D60C7E7B-8E82-4EFC-80B7-C82C73A8FEA4</gtr:id><gtr:title>Quantitative and logic modelling of molecular and gene networks.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaf558048290296295670b8a85ce7e98"><gtr:id>aaf558048290296295670b8a85ce7e98</gtr:id><gtr:otherNames>Le Nov?re N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-0056</gtr:issn><gtr:outcomeId>56bb0f2d5ecf17.86510106</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E39A92FC-BB64-48ED-87D9-CEBDF9BCB599</gtr:id><gtr:title>The role of MAPK signalling pathways in the response to endoplasmic reticulum stress.</gtr:title><gtr:parentPublicationTitle>Biochimica et biophysica acta</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6729b387bf4e554c2fee167548dc24df"><gtr:id>6729b387bf4e554c2fee167548dc24df</gtr:id><gtr:otherNames>Darling NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-3002</gtr:issn><gtr:outcomeId>546f510a42e8f6.55054748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4AFB4932-D867-41A7-9E29-61D51FB15014</gtr:id><gtr:title>Using chemical kinetics to model biochemical pathways.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaf558048290296295670b8a85ce7e98"><gtr:id>aaf558048290296295670b8a85ce7e98</gtr:id><gtr:otherNames>Le Nov?re N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>54648e8a338547.18985837</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F2B582A-C3D5-4D0D-9AAA-B73920105EC2</gtr:id><gtr:title>ERK1/2 inhibitors: New weapons to inhibit the RAS-regulated RAF-MEK1/2-ERK1/2 pathway.</gtr:title><gtr:parentPublicationTitle>Pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f30e607a2f14029f1decfbd34338e74a"><gtr:id>f30e607a2f14029f1decfbd34338e74a</gtr:id><gtr:otherNames>Kidger AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0163-7258</gtr:issn><gtr:outcomeId>5aa6aa1d319ab8.84660122</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F98932DD-29BB-4314-8CE0-64A91B44A998</gtr:id><gtr:title>MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c6a1d50ea11f9d6a6fc49721bd0ab613"><gtr:id>c6a1d50ea11f9d6a6fc49721bd0ab613</gtr:id><gtr:otherNames>Evans C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>546f5109b3fdc0.44060228</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B6CBA8A-2D57-4544-A39D-B02BDC1E15BA</gtr:id><gtr:title>Perturbations of PIP3 signalling trigger a global remodelling of mRNA landscape and reveal a transcriptional feedback loop.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/51585f72da0559dba579b0473aa0f917"><gtr:id>51585f72da0559dba579b0473aa0f917</gtr:id><gtr:otherNames>Kiselev VY</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>56ba0c70890431.29153792</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AC9ECB11-787E-4928-A662-C8C80B726A83</gtr:id><gtr:title>Promoting Coordinated Development of Community-Based Information Standards for Modeling in Biology: The COMBINE Initiative.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioengineering and biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/134f7f552ce0541c4693180f7bd85298"><gtr:id>134f7f552ce0541c4693180f7bd85298</gtr:id><gtr:otherNames>Hucka M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2296-4185</gtr:issn><gtr:outcomeId>56bb0f2fb03286.26850755</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>477B5A4B-7D3C-47EC-8994-B26FEA9D7386</gtr:id><gtr:title>Modeling Signaling Networks to Advance New Cancer Therapies.</gtr:title><gtr:parentPublicationTitle>Annual review of biomedical engineering</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66082b6031fcef10ba10469c8e828018"><gtr:id>66082b6031fcef10ba10469c8e828018</gtr:id><gtr:otherNames>Saez-Rodriguez J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1523-9829</gtr:issn><gtr:outcomeId>56459b6cf3b563.32188077</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1EE7ABEC-7889-43FA-A5D7-376D79103C5D</gtr:id><gtr:title>FGF signaling inhibition in ESCs drives rapid genome-wide demethylation to the epigenetic ground state of pluripotency.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dec6cf848835dc1cbdbd7ef7bee2cd34"><gtr:id>dec6cf848835dc1cbdbd7ef7bee2cd34</gtr:id><gtr:otherNames>Ficz G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>546f5057618294.06193227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F18FD80B-E8D5-4E79-8272-06FF49D4CEFD</gtr:id><gtr:title>PTEN Regulates PI(3,4)PSignaling Downstream of Class I PI3K.</gtr:title><gtr:parentPublicationTitle>Molecular cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32166a1af7e300ccef30545562aeb163"><gtr:id>32166a1af7e300ccef30545562aeb163</gtr:id><gtr:otherNames>Malek M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1097-2765</gtr:issn><gtr:outcomeId>5a7c6eb7c1cd71.88477176</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>101CF413-1434-43EF-8EB9-D54E264C0723</gtr:id><gtr:title>The health care and life sciences community profile for dataset descriptions.</gtr:title><gtr:parentPublicationTitle>PeerJ</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/704335841acdf87bc43b030443c20cf1"><gtr:id>704335841acdf87bc43b030443c20cf1</gtr:id><gtr:otherNames>Dumontier M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58bda186ddadc1.26400919</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B4E98FC3-E5F1-45BC-A862-1FB6F14FF94A</gtr:id><gtr:title>Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c92f1ca52279657b6aff9f15ffdfcd"><gtr:id>90c92f1ca52279657b6aff9f15ffdfcd</gtr:id><gtr:otherNames>Little AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>546f4fca916313.15697646</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F965E8D7-4D3B-4C87-A644-0CF7858B8D92</gtr:id><gtr:title>The systems biology format converter.</gtr:title><gtr:parentPublicationTitle>BMC bioinformatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56f5713ac7f18b823d9a90722ed664a1"><gtr:id>56f5713ac7f18b823d9a90722ed664a1</gtr:id><gtr:otherNames>Rodriguez N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-2105</gtr:issn><gtr:outcomeId>585d704fe3d9e8.61243251</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/B/000C0419</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>